ACI
RCUS icon

AMP Capital Investors’s Arcus Biosciences RCUS Stock Holding History

AMP Capital Investors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,700
Closed -$186K – 1311
2020
Q3 		$186K Buy
+10,700
New +$239K ﹤0.01% 1169

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AMP Capital Investors's RCUS Position: Q4 2020 in Review

AMP Capital Investors sold out of Arcus Biosciences (RCUS) in Q4 2020, closing a stake of 10,700 shares — an estimated $186K sold.

AMP Capital Investors first reported a position in RCUS in Q3 2020 and held it in 1 quarter. The position peaked at $186K in Q3 2020. 148 funds tracked by Wall St. Rank hold RCUS as of Q4 2020.

  • AMP Capital Investors reported no remaining Arcus Biosciences position as of Q4 2020 after selling out during the quarter.
  • AMP Capital Investors sold 10,700 Arcus Biosciences shares in Q4 2020, an estimated $186K.
  • AMP Capital Investors first reported a position in Arcus Biosciences in Q3 2020 and held it in 1 quarter.
  • AMP Capital Investors's Arcus Biosciences position peaked at $186K in Q3 2020.
  • 148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2020.

Based on AMP Capital Investors's 13F filing for Q4 2020, filed 12 Feb 2021.